Dr Reddy's CEO Erez Israeli expects the company to achieve a healthy performance in the second half of fiscal year 2026-27, contingent on resolving current issues with its semaglutide pipeline. Israeli also anticipates that the generics market for semaglutide will be ultra-competitive, with over 20 companies vying for market share.